Advent Capital Management Incyte Corp Transaction History

Advent Capital Management

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $304,250 - $419,900	-5,000 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$83.06 - $100.98 $2.87 Million - $3.48 Million	-34,500 Reduced 87.34%	5,000 $417,000
Q4 2017 Feb 13, 2018	SELL	$93.56 - $116.6 $1.03 Million - $1.28 Million	-11,000 Reduced 21.78%	39,500 $3.74 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $5.51 Million - $6.98 Million	50,500	50,500 $5.9 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Advent Capital Management , based on Form 13F filings with the SEC.

Stay updated on Advent Capital Management with notifications on news.